Health economic analyses taken over by the Danish Medicines Council
Since 1 January 2020, the Danish Medicines Council Secretariat has taken over the task of assessing health economic analyses in connection with recommendations by the Danish Medicines Council of new medicines and indicators.
This means that, in future, questions regarding the healtch economic part of applications for new medicines and indicators should be referred to the Danish Medicines Council Secretariat.
When the Danish Medicines Council has assessed the added clinical value, Amgros still negotiates the price of the medicine
Is there is a reasonable relationship between the added clinical value from a new pharmaceutical compared with the existing treatment, and the costs this entails?READ MORE
Negotiation of prices
When the Danish Medicines Council has determined the added clinical value of a new pharmaceutical, Amgros will negotiate with the applicantREAD MORE
Head of Business Intelligence and Health Economy
I’m responsible for operation and development of business intelligence and health economics. I make sure that our department can proudly claim to be the partner who gets things done.
Lasse Lund Gundtoft
I work as a negotiator for new pharmaceuticals and I coordinate Amgros' activities in relation to the Danish Medicines Council.